Aldeyra TherapeuticsALDX
ALDX
About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Employees: 9
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
164% more call options, than puts
Call options by funds: $2.18M | Put options by funds: $825K
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
66% more capital invested
Capital invested by funds: $118M [Q2] → $196M (+$78.4M) [Q3]
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
9% more funds holding
Funds holding: 103 [Q2] → 112 (+9) [Q3]
1.76% more ownership
Funds ownership: 60.0% [Q2] → 61.76% (+1.76%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for ALDX.
Financial journalist opinion
Neutral
Zacks Investment Research
1 week ago
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.
Neutral
Business Wire
2 weeks ago
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the Eyes Wide Open on Ophthalmology Panel at the Citi 2024 Global Healthcare Conference. The conference is being conducted in Miami, Florida December 2-5, 2024. D.
Positive
Zacks Investment Research
1 month ago
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Neutral
Business Wire
1 month ago
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for r.
Neutral
Business Wire
1 month ago
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024. Dr. Brady's conver.
Positive
Seeking Alpha
1 month ago
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Aldeyra conducted a Phase 3 trial, where reproxalap met its primary endpoint in DED patients.
Neutral
Business Wire
1 month ago
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the Disruptive Innovations Symposium during the Ocular Surgery News (OSN) New York Retina 2024 Meeting, which takes place in New York, New York November 8-10, 2024. Dr. Stryjew.
Neutral
Business Wire
2 months ago
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmission includes pr.
Neutral
Business Wire
3 months ago
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. Dr. Brady's conversation with Matthew Caufield, Director, Equity Research at H.C.
Positive
Seeking Alpha
3 months ago
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership
Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt. Aldeyra has an option agreement with AbbVie, potentially leading to significant milestone payments and a 60%/40% partnership if FDA approval is granted. Reproxalap offers immediate and long-term relief, a significant advantage over existing therapies like Xiidra and Restasis, enhancing its market potential.
Charts implemented using Lightweight Charts™